Ozempic provide will proceed to be restricted till the top of subsequent yr, in keeping with the newest recommendation from Novo Nordisk, Ozempic’s provider.
The Therapeutic Items Administration (TGA) mentioned Novo Nordisk has suggested that they’re persevering with to extend manufacturing capability, however it will take time to construct provide ranges to fulfill international and Australian demand.
The TGA mentioned the semaglutide product is authorized for the administration of kind 2 diabetes not adequately managed by different drugs, at the side of food regimen and train. A separate semaglutide product, Wegovy, is authorized to assist with power weight administration.
Diabetes Australia understands the numerous issues of Australians dwelling with kind 2 diabetes concerning the ongoing Ozempic scarcity and can proceed to advocate for prioritised entry for folks dwelling with diabetes.
Diabetes Australia has advocated for the TGA to analyze the shortages of various diabetes-related medicines and merchandise in recent times and redouble efforts to make sure Australians will be assured that provide chains are adequate to fulfill their wants.
The TGA has requested well being professionals to:
- think about the continued scarcity when prescribing Ozempic, inform sufferers that provide is anticipated to be restricted in 2025, and talk about different therapies when sufferers are unable to entry the drugs.
- prescribe and provide each Ozempic and Wegovy in keeping with their authorized indications.
Details about the Ozempic scarcity is offered from the TGA web site.
